The greatest monthly patient liability was incurred by chemo-radiotherapy patients, which ranged from $1617 to $2004 per month across cancer stages. Costs for lung cancer care are substantial, and Medicare is paying a smaller proportion of the total cost over time....
Objective: To determine the direct treatment cost of lung cancer management from progression to death from the viewpoint of the hospital.Methods: A retrospective descriptive study was performed. Data from 100 patients who died of lung cancer and who had received treatment from four different types ...
Additional costs: According to a study[11] published in the international journal Lung Cancer, the failure of initial treatment is associated with markedly increased costs. Patients needing additional rounds of treatment had total costs of$120,650,compared to$45,953for those receiving initial treatmen...
initial, continuing, and terminal), stratified by treatment, stage, and non- vs. small celllung cancer. Lung cancer-attributable costs were estimated by subtracting each patient's own pre-diagnosis costs. Costs were estimated as the sum of Medicare reimbursements (payments fromMedicare to the serv...
Incremental treatment costs in national cancer institute-sponsored clinical trials Concern about additional costs for direct patient care impedes efforts to enroll patients in clinical trials. But generalizable evidence substantiating the... Dana P,Goldman,Sandra H,Berry,Mary S,McCabe,... - 《Jama the...
The costs of these personalized therapies can be significant, and pharmacists can help patients find financing options or identify alternative choices and strategies to manage availability. Additionally, pharmacists have been shown to contribute to improved adherence rates, therapy optimization, patient ...
Second-line treatment options for patients with relapsed, extensive-stage small cell lung cancer (ES-SCLC) are limited, and even with currently available treatments, prognosis remains poor. Until recently, topotecan (a topoisomerase I inhibitor) was the only drug approved by the United States (US...
Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy BACKGROUND: Limited post-crizotinib treatment options for ALK-positive non-small cell lung cancer (NSCLC) might lead to poor survival and high economic bur... A Guérin,M ...
1 Approximately 85% of the cases will be non-small cell lung cancer (NSCLC), and 65% of patients will have advanced stage disease at the time of diagnosis.2, 3 For patients with advanced stage NSCLC and a preserved functional status the standard therapy is double agent platinum-based ...
Most Patients Can Keep Using GLP-1 Weight Loss Meds Before Surgeries Election Fears Are Keeping Americans Awake at Night, Survey Shows Check Your Cabinet: Some COVID Test Expiration Dates Have Been Extended, FDA Says Costs for MS, Parkinson's and Alzheimer's Meds Keep Rising Staying In: Did...